JR
Therapeutic Areas
Blueprint Medicines Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AYVAKIT (avapritinib) | Indolent Systemic Mastocytosis | Approved |
| Elenestinib (BLU-263) | Indolent Systemic Mastocytosis | Phase 3 |
| BLU-808 | Chronic Spontaneous & Inducible Urticaria | Planned |